1. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. (16th May 2019) Authors: Loibl, S; Untch, M; Burchardi, N; Huober, J; Sinn, B V; Blohmer, J -U; Grischke, E -M; Furlanetto, J; Tesch, H; Hanusch, C; Engels, K; Rezai, M; Jackisch, C; Schmitt, W D; von Minckwitz, G; Thomalla, J; Kümmel, S; Rautenberg, B; Fasching, P A; Weber, K Journal: Annals of oncology Issue: Volume 30:Number 8(2019) Page Start: 1279 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗